Heterologous expression and evaluation of novel Plasmodium falciparum transmission blocking vaccine candidates

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Heterologous expression and evaluation of novel Plasmodium falciparum transmission blocking vaccine candidates. / de Jong, Roos M; Singh, Susheel K; Teelen, Karina; van de Vegte-Bolmer, Marga; van Gemert, Geert-Jan; Stone, Will J R; Locke, Emily; Plieskatt, Jordan; Theisen, Michael; Bousema, Teun; Jore, Matthijs M.

In: Frontiers in Immunology, Vol. 13, 909060, 2022.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

de Jong, RM, Singh, SK, Teelen, K, van de Vegte-Bolmer, M, van Gemert, G-J, Stone, WJR, Locke, E, Plieskatt, J, Theisen, M, Bousema, T & Jore, MM 2022, 'Heterologous expression and evaluation of novel Plasmodium falciparum transmission blocking vaccine candidates', Frontiers in Immunology, vol. 13, 909060. https://doi.org/10.3389/fimmu.2022.909060

APA

de Jong, R. M., Singh, S. K., Teelen, K., van de Vegte-Bolmer, M., van Gemert, G-J., Stone, W. J. R., Locke, E., Plieskatt, J., Theisen, M., Bousema, T., & Jore, M. M. (2022). Heterologous expression and evaluation of novel Plasmodium falciparum transmission blocking vaccine candidates. Frontiers in Immunology, 13, [909060]. https://doi.org/10.3389/fimmu.2022.909060

Vancouver

de Jong RM, Singh SK, Teelen K, van de Vegte-Bolmer M, van Gemert G-J, Stone WJR et al. Heterologous expression and evaluation of novel Plasmodium falciparum transmission blocking vaccine candidates. Frontiers in Immunology. 2022;13. 909060. https://doi.org/10.3389/fimmu.2022.909060

Author

de Jong, Roos M ; Singh, Susheel K ; Teelen, Karina ; van de Vegte-Bolmer, Marga ; van Gemert, Geert-Jan ; Stone, Will J R ; Locke, Emily ; Plieskatt, Jordan ; Theisen, Michael ; Bousema, Teun ; Jore, Matthijs M. / Heterologous expression and evaluation of novel Plasmodium falciparum transmission blocking vaccine candidates. In: Frontiers in Immunology. 2022 ; Vol. 13.

Bibtex

@article{039f2c4b695549feba035c4627ee4b84,
title = "Heterologous expression and evaluation of novel Plasmodium falciparum transmission blocking vaccine candidates",
abstract = "Malaria transmission blocking vaccines (TBV) aim to induce antibodies that can interrupt Plasmodium falciparum development in the mosquito midgut and thereby prevent onward malaria transmission. A limited number of TBV candidates have been identified and only three (Pfs25, Pfs230 and Pfs48/45) have entered clinical testing. While one of these candidates may emerge as a highly potent TBV candidate, it is premature to determine if they will generate sufficiently potent and sustained responses. It is therefore important to explore novel candidate antigens. We recently analyzed sera from naturally exposed individuals and found that the presence and/or intensity of antibodies against 12 novel putative surface expressed gametocyte antigens was associated with transmission reducing activity. In this study, protein fragments of these novel TBV candidates were designed and heterologously expressed in Drosophila melanogaster S2 cells and Lactococcus lactis. Eleven protein fragments, covering seven TBV candidates, were successfully produced. All tested antigens were recognized by antibodies from individuals living in malaria-endemic areas, indicating that native epitopes are present. All antigens induced antigen-specific antibody responses in mice. Two antigens induced antibodies that recognized a native protein in gametocyte extract, and antibodies elicited by four antigens recognized whole gametocytes. In particular, we found that antigen Pf3D7_0305300, a putative transporter, is abundantly expressed on the surface of gametocytes. However, none of the seven novel TBV candidates expressed here induced an antibody response that reduced parasite development in the mosquito midgut as assessed in the standard membrane feeding assay. Altogether, the antigen fragments used in this study did not prove to be promising transmission blocking vaccine constructs, but led to the identification of two gametocyte surface proteins that may provide new leads for studying gametocyte biology.",
author = "{de Jong}, {Roos M} and Singh, {Susheel K} and Karina Teelen and {van de Vegte-Bolmer}, Marga and {van Gemert}, Geert-Jan and Stone, {Will J R} and Emily Locke and Jordan Plieskatt and Michael Theisen and Teun Bousema and Jore, {Matthijs M}",
note = "Copyright {\textcopyright} 2022 de Jong, Singh, Teelen, van de Vegte-Bolmer, van Gemert, Stone, Locke, Plieskatt, Theisen, Bousema and Jore.",
year = "2022",
doi = "10.3389/fimmu.2022.909060",
language = "English",
volume = "13",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - Heterologous expression and evaluation of novel Plasmodium falciparum transmission blocking vaccine candidates

AU - de Jong, Roos M

AU - Singh, Susheel K

AU - Teelen, Karina

AU - van de Vegte-Bolmer, Marga

AU - van Gemert, Geert-Jan

AU - Stone, Will J R

AU - Locke, Emily

AU - Plieskatt, Jordan

AU - Theisen, Michael

AU - Bousema, Teun

AU - Jore, Matthijs M

N1 - Copyright © 2022 de Jong, Singh, Teelen, van de Vegte-Bolmer, van Gemert, Stone, Locke, Plieskatt, Theisen, Bousema and Jore.

PY - 2022

Y1 - 2022

N2 - Malaria transmission blocking vaccines (TBV) aim to induce antibodies that can interrupt Plasmodium falciparum development in the mosquito midgut and thereby prevent onward malaria transmission. A limited number of TBV candidates have been identified and only three (Pfs25, Pfs230 and Pfs48/45) have entered clinical testing. While one of these candidates may emerge as a highly potent TBV candidate, it is premature to determine if they will generate sufficiently potent and sustained responses. It is therefore important to explore novel candidate antigens. We recently analyzed sera from naturally exposed individuals and found that the presence and/or intensity of antibodies against 12 novel putative surface expressed gametocyte antigens was associated with transmission reducing activity. In this study, protein fragments of these novel TBV candidates were designed and heterologously expressed in Drosophila melanogaster S2 cells and Lactococcus lactis. Eleven protein fragments, covering seven TBV candidates, were successfully produced. All tested antigens were recognized by antibodies from individuals living in malaria-endemic areas, indicating that native epitopes are present. All antigens induced antigen-specific antibody responses in mice. Two antigens induced antibodies that recognized a native protein in gametocyte extract, and antibodies elicited by four antigens recognized whole gametocytes. In particular, we found that antigen Pf3D7_0305300, a putative transporter, is abundantly expressed on the surface of gametocytes. However, none of the seven novel TBV candidates expressed here induced an antibody response that reduced parasite development in the mosquito midgut as assessed in the standard membrane feeding assay. Altogether, the antigen fragments used in this study did not prove to be promising transmission blocking vaccine constructs, but led to the identification of two gametocyte surface proteins that may provide new leads for studying gametocyte biology.

AB - Malaria transmission blocking vaccines (TBV) aim to induce antibodies that can interrupt Plasmodium falciparum development in the mosquito midgut and thereby prevent onward malaria transmission. A limited number of TBV candidates have been identified and only three (Pfs25, Pfs230 and Pfs48/45) have entered clinical testing. While one of these candidates may emerge as a highly potent TBV candidate, it is premature to determine if they will generate sufficiently potent and sustained responses. It is therefore important to explore novel candidate antigens. We recently analyzed sera from naturally exposed individuals and found that the presence and/or intensity of antibodies against 12 novel putative surface expressed gametocyte antigens was associated with transmission reducing activity. In this study, protein fragments of these novel TBV candidates were designed and heterologously expressed in Drosophila melanogaster S2 cells and Lactococcus lactis. Eleven protein fragments, covering seven TBV candidates, were successfully produced. All tested antigens were recognized by antibodies from individuals living in malaria-endemic areas, indicating that native epitopes are present. All antigens induced antigen-specific antibody responses in mice. Two antigens induced antibodies that recognized a native protein in gametocyte extract, and antibodies elicited by four antigens recognized whole gametocytes. In particular, we found that antigen Pf3D7_0305300, a putative transporter, is abundantly expressed on the surface of gametocytes. However, none of the seven novel TBV candidates expressed here induced an antibody response that reduced parasite development in the mosquito midgut as assessed in the standard membrane feeding assay. Altogether, the antigen fragments used in this study did not prove to be promising transmission blocking vaccine constructs, but led to the identification of two gametocyte surface proteins that may provide new leads for studying gametocyte biology.

U2 - 10.3389/fimmu.2022.909060

DO - 10.3389/fimmu.2022.909060

M3 - Journal article

C2 - 35812379

VL - 13

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

M1 - 909060

ER -

ID: 313473675